Effect of topical cyclosporin A on herpetic stromal keratitis in a mouse model

Cornea

Volumn 27, Issue 4, 2008, Pages 454-460

  Yoon, Kyung Chul ^a,c   Heo, Hwan ^a   Kang, In Seong ^a   Lee, Min Chul ^a   Kim, Kyung Keun ^a   Park, Soo Hyun ^b   Cho, Kyoung Oh ^b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

^c Chonnam National University Medical School   (South Korea)

Author keywords

Cyclosporin A; Eyedrops; Herpetic stromal keratitis

Indexed keywords

CASTOR OIL; CYCLOSPORIN A; EYE DROPS; FLUOROMETHOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HERPES SIMPLEX KERATITIS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SLIT LAMP; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ANIMALS; CD4 LYMPHOCYTE COUNT; CORNEAL STROMA; CYCLOSPORINE; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HERPESVIRUS 1, HUMAN; IMMUNOSUPPRESSIVE AGENTS; KERATITIS, HERPETIC; MICE; MICE, INBRED BALB C; OPHTHALMIC SOLUTIONS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 42549130371     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318160602d     Document Type: Article

References (42)

1. + cells are key participants in the development of recurrent herpetic stromal keratitis in mice. Microb Pathog. 2002;32:255-262.
2. Newell CK, Martin S, Sendele D, et al. Herpes simplex virus-induced stromal keratitis: role of T-lymphocyte subsets in immunopathology. J Virol. 1989;63:769-775.
3. Gangappa S, Deshpande SP, Rouse BT. Bystander activation of CD4(+) T cells can represent an exclusive means of immunopathology in a virus infection. Eur J Immunol. 1999;29:3674-3682.
4. + T-cell type 1 and type 2 cytokines in the HSK-1 infected cornea. Graefes Arch Clin Exp Ophthalmol. 1999;237:399-406.
5. Thomas J, Gangappa S, Kanangat S, et al. On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis. J Immunol. 1997;158:1383-1391.
6. Bauer D, Mrzyk S, van Rooijen N, et al. Macrophage-depletion influences the course of murine HSK-1 keratitis. Curr Eye Res. 2000;20:45-53.
7. Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol. 2005;89:1363-1367.
8. Nussenblatt RB, Palestine AG. Cyclosporin: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986;31:159-169.
9. Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporine A. Background, immunology, and pharmacology. Cornea. 1990;9:184-195.
10. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporin ophthalmic elusion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631-639.
11. Avunduk AM, Avunduk MC, Erdol H, et al. Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica. 2001;215:290-293.
12. Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporine 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology. 2004;111:476-482.
13. Bebelli U, Ross JR, Nardi M, et al. Corneal neovascularization induced by xenograft or chemical cautery. Inhibition by cyclosporin A. Invest Ophthalmol Vis Sci. 1997;38:274-282.
14. Rao SN. Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol. 2006;141:771-772.
15. Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporine A: pilot study. Graefes Arch Clin Exp Ophthalmol. 1999;237:435-438.
16. Gunduz K, Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res. 1997;29:405-408.
17. Hook LM, Lubinski JM, Jiang M, et al. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody. J Virol. 2006;80:4038-4046.
18. Huster KM, Panoutsakopoulou V, Prince K, et al. T cell-dependent and -independent pathways to tissue destruction following herpes simplex virus-1 infection. Eur J Immunol. 2002;32:1414-1419.
19. Heiligenhaus A, Li H, Schmitz A, et al. Improvement of herpetic stromal keratitis with fumaric acid derivative is associated with systemic indication of T helper 2 cytokines. Clin Exp Immunol. 2005;142:180-187.
20. Heiligenhaus A, Bauer D, Meller D, et al. Improvement of HSV-1 necrotizing keratitis with amniotic membrane transplantation. Invest Ophthalmol Vis Sci. 2001;42:1969-1974.
21. Heiligenhaus A, Li HF, Yang Y, et al. Transplantation of amniotic membrane in murine herpes stromal keratitis modulates matrix metalloproteinases in the cornea. Invest Ophthalmol Vis Sci. 2005;46:4079-4085.
22. Dana MR, Zhu SN, Yamada J. Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea. 1998;17:403-409.
23. Sonoda KH, Nakao S, Nakamura T, et al. Cellular events in the normal and inflamed cornea. Cornea. 2005;24(Suppl 1):S50-S54.
24. Banerjee K, Biswas PS, Rouse T. Elucidating the protective and pathologic T cell species in the virus-induced corneal immunoinflammatory condition herpetic stromal keratitis. J Leukoc Biol. 2005;77:24-32.
25. Deshpande S, Zheng M, Lee S, et al. Bystander activation involving T lymphocyte in herpetic stromal keratitis. J Immunol. 2001;167:2902-2910.
26. Shi W, Chen M, Xie L. Amniotic membrane transplantation combined with antiviral and steroid therapy for herpes necrotizing stromal keratitis. Ophthalmology. 2007;114:1476-1481.
27. Wilhelmus KR, Gee L, Hauck WW, et al. Herpetic eye disease study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994;101:1883-1896.
28. Liegner JT, Yee RW, Wild JH. Topical cyclosporine therapy for ulcerative keratitis associated with rheumatoid arthritis. Am J Ophthalmol. 1990;109:610-612.
29. Rheinhard T, Sundmacher R. Topical cyclosporine A in Thygeson's superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol. 1999;237:109-112.
30. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Topical cyclosporine A 0.5% as a possible new treatment for superior limbic keratoconjunctivitis. Ophthalmology. 2003;110:1578-1581.
31. Zhao JC, Jin XY. Immunological analysis and treatment of Mooren's ulcer with cyclosporine A applied topically. Cornea. 1993;12:481-488.
32. Perry HD, Doshi SJ, Donnenfeld ED, et al. Topical cyclosporine A in the management of therapeutic keratoplasty for mycotic keratitis. Cornea. 2002;21:161-163.
33. Doan S, Gabison E, Gatinel D, et al. Topical cyclosporine A in severe steroid-dependent childhood phlyctenular keratoconjunctivitis. Am J Ophthalmol. 2006;141:62-66.
34. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25:171-175.
35. Ilari L, Daya S. Long-term outcomes of keratolimbal allograft for the treatment of severe ocular surface disorders. Ophthalmology. 2002;109:1278-1284.
36. Boisjoly HM, Woog JJ, Pavan-Langston D, et al. Prophylactic topical cyclosporine in experimental herpetic stromal keratitis. Arch Ophthalmol. 1984;102:1804-1807.
37. Naito T, Nitta K, Kinouchi Y, et al. Effects of 9-(1,3-dihydroxy-2- propoxymethyl) guanine (DHPG) eye drops and cyclosporine eye drops in the treatment of herpetic stromal keratitis in rabbits. Curr Eye Res. 1991;10(Suppl):201-203.
38. O'Brien WJ, Taylor JL. Therapeutic response of herpetic simplex virus-induced corneal edema to trifluridine in combination with immunosuppressive agents. Invest Ophthalmol Vis Sci. 1991;32:2455-2461.
39. Meyers-Elliott RH, Chitjian PA, Billups CL. Effect of cyclosporine A on the corneal inflammatory response in herpes simplex virus keratitis. Exp Eye Res. 1987;45:281-303.
40. Meyers-Elliott RH, Chitjian PA, Billups CB. Effect of cyclosporine A on clinical and immunological parameters in herpes simplex keratitis. Invest Ophthalmol Vis Sci. 1987;28:1170-1180.
41. Vahlne A, Larsson PA, Horal P, et al. Inhibition of herpes simplex virus production in vitro by cyclosporin A. Arch Virol. 1992;122:61-75.
42. Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppress hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl. 2006;12:51-57.